Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | FLT4 | P35916 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14460560 | 0.80 | ALDH1A1 (0.71) | ALDH1A1HPGDKMT2AMEN1GAA | |
| SCHEMBL6792122 | 0.73 | HDAC7 (0.59) | ALDH1A1RAB9AKMT2AKDM4ENPC1 | |
| SCHEMBL328219 | 0.73 | SMN1; SMN2 (0.56) | ALDH1A1RAB9AKMT2AKDM4ENPC1 | |
| Oxalic Acid SCHEMBL2333397 | 0.73 | KMT2A (0.59) | ALDH1A1RAB9AKMT2AMEN1KDM4E | |
| SCHEMBL5504399 | 0.72 | SMN1; SMN2 (0.58) | ALDH1A1RAB9AKMT2AMEN1KDM4E | |
| Hydrochloric Acid SCHEMBL19547889 | 0.70 | SMN1; SMN2 (0.57) | ALDH1A1RAB9AKMT2AMEN1KDM4E | |
| SCHEMBL24997800 | 0.69 | TAS1R3 (0.61) | ALDH1A1RAB9AHPGDKMT2AGAA | |
| SCHEMBL4926140 | 0.69 | SMN1; SMN2 (0.51) | ALDH1A1RAB9AKMT2AKDM4ENPC1 | |
| SCHEMBL10602569 | 0.69 | SMN1; SMN2 (0.64) | ALDH1A1RAB9AHPGDKMT2AKDM4E | |
| SCHEMBL16523453 | 0.69 | TAS1R3 (0.54) | ALDH1A1RAB9AHPGDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160067257-A1 | SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY | THE WISTAR INSTITUTE (US) | 2016-03-10 | — | — | US | disclosed |
| US-9234230-B2 | Screening method and compounds for modulating telomerase activity | THE WISTAR INSTITUTE (US) | 2016-01-12 | — | — | US | disclosed |
| US-8518940-B2 | FP-pocket-binding effectors and methods for using the same to modulate telomerase activity | THE WISTAR INSTITUTE (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120309759-A1 | Screening Method and Compounds for Modulating Telomerase Activity | THE WISTAR INSTITUTE (US) | 2012-12-06 | — | — | US | disclosed |
| US-20100158798-A1 | FP-Pocket-Binding Effectors and Methods for Using the Same to Modulate Telomerase Activity | THE WISTAR INSTITUTE | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309759-A1 | Screening Method and Compounds for Modulating Telomerase Activity | TERT, TERB1, TERF2 | ALDH1A1 3360/4885RAB9A 3522/4885HPGD 2869/4885 |
| US-20100158798-A1 | FP-Pocket-Binding Effectors and Methods for Using the Same to Modulate Telomerase Activity | TERF2IP, TERF2, TERT | ALDH1A1 4190/4885RAB9A 3545/4885HPGD 3483/4885 |
| US-20160067257-A1 | SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY | TERT, TERB1, TERF2 | ALDH1A1 3360/4885RAB9A 3522/4885HPGD 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.